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Objective - Liver X Receptors (LXRα, LXRβ) are master regulators of cholesterol homeostasis. In the 
endothelium, perturbations of cell cholesterol impact on fundamental processes. We therefore 
assessed the effects of LXR activation on endothelial functions related to angiogenesis in vitro and in 
vivo. 
 
Methods and Results - LXR agonists (T0901317, GW3965) blunted migration, tubulogenesis and 
proliferation of human umbilical vein endothelial cells (HUVEC). By affecting endothelial cholesterol 
homeostasis, LXR activation impaired the compartmentation of VEGF receptor 2 (VEGFR2) in lipid 
rafts/caveolae and led to defective phosphorylation and downstream signaling of VEGFR2 upon 
VEGF-A stimulation. Consistently, the anti-angiogenic actions of LXR agonists could be prevented 
by co-administration of exogenous cholesterol. LXR agonists reduced endothelial sprouting from 
wild-type but not from LXRα-/-/LXRβ-/- knock-out aortas and blunted the vascularization of implanted 
angioreactors in vivo. Furthermore, T0901317 reduced the growth of LLC-1 tumor grafts in mice by 
impairing angiogenesis. 
 
Conclusions - Pharmacological activation of endothelial LXRs reduces angiogenesis by restraining 
cholesterol-dependent VEGFR2 compartmentation and signaling. Thus, administration of LXR 




angiogenesis, cholesterol, liver X receptor (LXR), VEGF, lipid rafts 




Liver X Receptors α and β (LXRα/NR1H3, LXRβ/NR1H2) are Retinoid X Receptor α (RXRα/ 
NR2B1) heterodimers belonging to the nuclear hormone receptor superfamily. Through coordinate 
transcriptional actions, LXRs orchestrate cellular and systemic cholesterol homeostasis.1 LXRs reduce 
cholesterol absorption, inhibit cholesterol synthesis and favor cholesterol output via reverse transport 
and bile secretion. Endogenous LXR agonists such as 22(R)-, 24- and 25-hydroxycholesterol, are 
formed upon cholesterol loading of cells and mediate this physiological feedback loop.2 Furthermore, 
LXR activation with synthetic agonists (e.g. T0901317, GW3965) exerts beneficial effects in 
atherosclerosis.3-6 
LXRs affect cell biology well beyond cholesterol metabolism. For instance, the anti-atherosclerotic 
properties of  LXR agonists also involve anti-inflammatory actions.7 Moreover, LXR agonists can 
restrain the proliferation of several cell types by affecting cell cycle control and pro-survival 
pathways.8-14 The precise mechanisms linking these complex effects to cholesterol homeostasis are 
largely unknown. One possibility is that LXR-dependent cholesterol mobilization may affect structure 
and dynamics of specific membrane and vesicular compartments. Indeed, T0901317 has been shown 
to reduce size and associated signaling of lipid rafts, cholesterol-enriched domains of the plasma 
membrane constituting fundamental signaling hubs for multiple transduction pathways.13, 15  
Administration of LXR agonists can impair multicellular processes that involve angiogenesis, such as 
liver regeneration and tumor growth.9, 13, 16 We and others have reported that endothelial cells express 
functional LXRs, with LXRβ representing the most important LXR isoform in this cell type.17-19 
Endothelial cells are particularly sensitive to cholesterol levels, given their wide membrane surface 
and richness in lipid rafts/caveolae. In line with this view, impairment of cholesterol homeostasis with 
itraconazole or cyclodextrin have been previously shown to affect VEGF receptor-2 (VEGFR2, Flk-
1/KDR) signaling in endothelial cells.20, 21 Taken together, these findings infer that the tissue actions 
of LXR agonists may also involve so far unappreciated anti-angiogenic effects. 
Herein, we show that the pharmacological activation of endothelial LXRs is anti-angiogenic, as a 
result of synergistic reductions in cell migration, tubulogenesis and proliferation. The anti-angiogenic 
effects of LXR agonists involve endothelial cholesterol depletion and impaired VEGFR2 
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compartmentation and signaling. These findings highlight the potential for LXR-targeted therapeutic 
interventions in conditions of pathological angiogenesis. 
 
METHODS 
A full description of experimental methods is provided online (Supplementary Information). 
 
Gene expression analysis 
RNA was extracted using affinity columns (Qiagen) or TRIzol (Invitrogen). Microarray gene 
expression profiling was performed with HG-U133 Plus 2.0 microarrays (Affymetrix).19 For 
quantitative reverse transcription real time-PCR (qRT-PCR), mRNA levels were analyzed using the 2-
ΔΔCt relative quantification system using 18S rRNA as housekeeping gene. Gene silencing was 
performed with shRNA Mission RNA interference vectors (Sigma) against LXRβ (Target Set 
NM_007121) or scramble shRNA.  
 
Cell cholesterol 
Lipids were extracted using chloroform:isopropanol:NP-40 (7:11:0.1). After homogenization and 
spinning, the organic phase was dried and suspended in a reaction mix containing cholesterol oxidase 




HUVEC were fixed with 4% PFA, blocked and incubated with anti-caveolin-1 (Santacruz) and anti-
VEGFR2 (R&D systems) antibodies, followed by incubation with secondary antibodies (Molecular 
Probes). Nuclei were counterstained with DAPI (Molecular Probes). Images were captured with a 
Leica AF6000 workstation equipped with a TIRF module and analyzed with ImageJ software. Tumor 
sections were incubated with anti-ABCA1 (Novus Biological) and/or anti-CD31 (BD Biosciences) 
antibodies. Images were acquired by using a Leica TCS SP2 AOBS confocal microscope and 
analyzed with Leica Confocal Software. 





For fractionation, cell lysates were adjusted to 45% sucrose by the addition of  90% sucrose and 
placed into ultracentrifugation tubes. A 5-35% sucrose discontinuous gradient was formed above and 
samples were centrifuged at 45x103 rpm for 16 hours at 4°C in a SW-55Ti rotor (Beckman). Ten 
fractions were collected from the top of each gradient. 
 
Migration and tubulogenesis assays 
HUVEC migration was assayed in a Boyden’s chamber with a gelatin-coated polycarbonate 
membrane. The lower compartment of the chamber was filled with EBM-2 medium (Lonza) 
containing VEGF-A (10 ng/mL). HUVECs were serum-starved overnight in the presence of the 
indicated compounds and then added to the upper compartment of the chamber. After 5 hours of 
incubation, the membrane was fixed and stained for microscopic analysis.  
Tubulogenesis assays were performed in solidified basement membrane matrix (Matrigel, BD 
Biosciences). After incubation with the indicated compounds, HUVEC were seeded and overlaid with 
EGM-2 medium (Lonza) containing the indicated compounds. After 8 hours, tubular structures were 
microscopically examined and photographed (Leica) for subsequent processing.  
 
Cell viability and cell cycle  
Cell viability was determined with the MTT assay (Roche). For apoptosis, annexin-positive HUVEC 
were detected using Annexin V-PE apoptosis kit (Merck). HUVEC proliferation rate and cell cycle 
were evaluated with the Click-iT EdU flow cytometry assay kit (Invitrogen) and propidium iodide 
(PI) staining, as described.22  
 
Animal studies 
Wild-type mice were 8-12 week-old female C57BL/6. The generation of LXRα-/-/LXRβ-/- mice has 
been previously described.23, 24 Animal procedures were approved by the local Ethical Committee.  
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Aortic ring angiogenic assay 
Thoracic aortas were removed from 8-12 week-old mice and incubated in serum-free medium with 
treatment compounds.25 Rings were transferred to Matrigel-coated culture dishes and covered with 
endothelial growth medium containing the indicated compounds. Tubular structures were examined 
with an inverted-phase contrast microscope and photographed (Leica) for subsequent processing.  
 
In vivo neoangiogenesis 
In vivo neoangiogenesis was performed using a modified Directed In vivo Angiogenesis Assay 
(DIVAA, Trevigen). On day 14, mice were euthanized and angioreactors were dissected. The 
vascularized basement membrane extract of each angioreactor was recovered and digested using 




For LLC-1 tumor grafts, 106 cells were injected subcutaneously into the back of 8-12 week-old female 
C57BL/6 mice. After one week, mice were randomized into a treatment group (T0901317 in 0.5% 
carboxymethyl cellulose-0.25% Tween 20, 20 mg/kg i.p. q.d.) and a control group (same amount of 
vehicle). Tumor growth was checked daily by caliper measurement. Mice were euthanized after one 
week of treatment.  
 
Data analysis 
Quantification of tubular structures was performed with WinRhizo Pro software (Regent 
Instruments).26 Quantification of immunofluorescence microphotographs was performed with ImageJ 
software (NIH). Data are presented as average ± standard error of the mean (SEM). Statistical 
significance was tested with unpaired Student’s t-test or one-way ANOVA with post-hoc analysis. 
The number of corresponding experimental replicates is provided in each figure legend. 
 
RESULTS 
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LXR activation reduces HUVEC cholesterol 
Human endothelial cells express functional LXRs.19 Gene expression profiling by microarray 
(Supplementary Figure IA) and real-time PCR (Figure 1A-E) indicated that treatment of HUVEC with 
the synthetic LXR agonist T0901317 modulated the mRNA expression of key genes involved in 
cholesterol trafficking: ATP-binding cassette sub-family A member 1 (ABCA1), ATB-binding 
cassette sub-family G member 1 (ABCG1), inducible degrader of the low-density lipoprotein receptor 
(IDOL), cholesteryl ester transfer protein (CETP) and sterol regulatory element binding transcription 
factor 1 (SREBP1c). The up-regulation of these genes was blunted by shRNA-mediated silencing of 
LXRβ (Supplementary Figures IB-C and II), thus confirming that ABCA1, ABCG1, IDOL, CETP and 
SREBP1c are bona fide LXR targets also in endothelial cells. 
In line with transcriptional data, T0901317 caused a robust protein induction of cholesterol 
transporters ABCA1 and ABCG1 (Figure 1F), which mediate cholesterol efflux and reverse 
cholesterol transport.27, 28 Instead, CETP and SREBP1c protein levels were only  marginally affected 
by T0901317 in HUVEC. Accordingly, T0901317 reduced HUVEC cholesterol content dose-
dependently (Figure 1G). 
 
LXR activation inhibits endothelial migration and tubulogenesis 
Modifications in endothelial cholesterol balance and trafficking have been shown to affect key 
biological processes.21, 29, 30 To assess the impact of LXR activation on endothelial angiogenesis, we 
first examined the effect of different LXR agonists on VEGF-A induced migration of HUVEC. LXR 
agonists GW3965 and T0901317 reduced migration dose-dependently compared to vehicle (Figure 
2A). To rule out off-target effects of LXR-activating compounds, HUVEC migration was also 
evaluated in the background of LXR silencing. While T0901317 reduced the migration of HUVEC 
infected with scramble shRNA, T0901317 did not affect the migration of LXRβ-silenced HUVEC 
(Figure 2B). 
HUVEC treated with GW3965 or T0901317 also showed a significant impairment in Matrigel 
tubulogenesis. GW3965 and T0901317 reduced average tubule length by 47±14% and 55±10% 
(p<0.05) (Figure 2C), and fork number by 63±9% and 68±11% (p<0.05) (Supplementary Figure IIIA) 
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respectively compared to vehicle. A similar effect was also produced by natural LXR agonist 22-
hydroxycholesterol (Supplementary Figure IIIB). Tubulogenesis was unchanged by T0901317 when 
HUVEC were co-incubated with exogenous cell-soluble cholesterol, thus suggesting that LXR 
activation impairs in vitro angiogenesis by affecting cell cholesterol homeostasis (Figure 2C and 
Supplementary Figure IIIA). Furthermore, T0901317 reduced tubulogenesis of HUVEC infected with 
scramble shRNA but not with LXRβ-targeting shRNA (Figure 2D). Taken together, these findings 
suggested that inhibition of endothelial migration and morphogenesis by LXR agonists is mediated by 
LXR-specific effects on cell cholesterol homeostasis.  
  
LXR activation inhibits endothelial proliferation without affecting apoptosis 
Besides motility, angiogenesis involves endothelial proliferation. As LXR agonists have been shown 
to reduce cell cycle progression in non-endothelial cells,8-11, 14 we assessed the effect of LXR agonists 
on HUVEC proliferation. GW3965 and T0901317 reduced HUVEC proliferation dose-dependently 
(Figure 3A). A similar effect was also produced by natural LXR agonist 22-hydroxycholesterol 
(Supplementary Figure IIIC). T0901317 reduced the protein levels of cyclins A and D1 and increased 
the protein levels of cyclin-dependent kinase inhibitor p27/Kip-1 (Figure 3B), indicating that LXR 
activation specifically perturbs cell cycle progression, as previously reported in other cell types.14, 31, 32 
However, T0901317 did not cause apoptosis (Figure 3C). Incubation of HUVEC with T0901317 
specifically restrained the G1-S cell cycle transition, as assessed by PI staining (Figure 3D), and 
reduced the DNA incorporation of a thymidine analogue (Figure 3E). The effect of T0901317 on G1-S 
transition and DNA synthesis was relieved by co-incubation of HUVEC with exogenous cell-soluble 
cholesterol (Figures 3D-E), thus indicating that LXR activation impairs endothelial cell cycle and 
proliferation by affecting cell cholesterol homeostasis. 
 
LXR activation reduces signaling of VEGFR2 
The observed effects of  LXR agonists in endothelial cells suggested the involvement of LXR in the 
angiogenic signaling. As previously reported in macrophages, T0901317 up-regulated the mRNA 
expression of VEGF-A also in HUVEC (Supplementary Figure IVA).33 However, the protein levels of 
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VEGF-A were unchanged by T0901317 in HUVEC (Supplementary Figure IVB). The mRNA and 
protein expression of VEGFR2, the pivotal VEGF receptor controlling angiogenesis,34 were not 
affected by T0901317 (Supplementary Figure IVC and Figure 4A). However, treatment of HUVEC 
with T0901317 blunted the functional activation of VEGFR2 by VEGF-A, as demonstrated by 
reduced phosphorylation of VEGFR2 on Tyr1175 and by reduced phosphorylation of phospholipase 
Cγ (PLCγ), a key mediator of VEGFR2-dependent angiogenic responses (Figure 4A).34 VEGF-A-
dependent phosphorylation of VEGFR2 and PLCγ was unchanged by T0901317 when HUVEC were 
co-incubated with exogenous cell-soluble cholesterol (Figure 4B-C), suggesting that LXR activation 
restrains VEGFR2 signaling by affecting cell cholesterol homeostasis. In line with this finding, the 
inhibitory effect of T0901317 on VEGF-A/VEGFR2-driven chemotaxis was specifically attenuated 
by addition of exogenous cell-soluble cholesterol (Supplementary Figures IVD). On the contrary, 
T0901317 treatment did not affect the migration of HUVEC stimulated by fibronectin in a haptotaxis 
assay (Supplementary Figure IVE). 
 
LXR activation reduces compartmentation of VEGFR2 in lipid rafts/caveolae 
Cholesterol depletion by T0901317 has been associated with a decrease in lipid raft size and 
signaling.13 We thus tested the hypothesis that T0901317 may affect VEGFR2 signaling by impairing 
its compartmentation in lipid rafts/caveolae. We analyzed the cell surface distribution of caveolar 
rafts, visualized by caveolin-1 staining, and of VEGFR2, by Total Internal Reflection Fluorescence 
(TIRF) microscopy. Treatment of HUVEC with T0901317 reduced the caveolin-1 positive area by 
53±8% (p<0.05) (Figures 4D-E), indicating a depletion in endothelial lipid rafts/caveolae. 
Furthermore, the amount of VEGFR2 localized in caveolar structures was reduced by 54±7% 
(p<0.05) (Figures 4D and 4F). The effect of T0901317 on caveolin-1 and VEGFR2 compartmentation 
was blunted by addition of exogenous cell-soluble cholesterol (Figures 4E-F). Membrane 
fractionation experiments confirmed that T0901317 displaced VEGFR2 from the buoyant flotillin-2 
and caveolin-1 positive fractions (1-3), representing endothelial lipid rafts/caveolae. Instead, the 
amount of VEGFR2 in the heavier, binding immunoglobulin protein (BiP)-positive fractions, 
representing the endoplasmic reticulum, was not affected (Figures 4G-H). Co-incubation of HUVEC 
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with exogenous cell-soluble cholesterol attenuated the T0901317-dependent depletion of VEGFR2 in 
lipid rafts/caveolae (Figure 4I), indicating that LXR activation modifies VEGFR2 membrane 
compartmentation by affecting cell cholesterol homeostasis. 
 
LXR activation inhibits endothelial sprouting and in vivo neoangiogenesis 
The impact of LXR agonists on angiogenesis was next assayed ex vivo and in vivo. Incubation of 
mouse aortic rings with GW3965 or T0901317 reduced ex vivo endothelial sprouting by 89±2% and 
73±10% respectively compared to vehicle (p<0.05). However, endothelial sprouting was unchanged 
by T0901317 when aortic rings were co-incubated with cholesterol, indicating that LXR activation 
impairs endothelial sprouting through cholesterol depletion (Figure 5A). T0901317 reduced 
endothelial sprouting when applied to aortic rings obtained from wild-type mice but not to rings 
obtained from mice deficient for LXRs (LXRα-/-/LXRβ-/-) (Figure 5B), thus confirming  that the anti-
angiogenic effect of T0901317 is LXR-specific. In vivo neoangiogenesis was next assessed through 
the subcutaneous implantation in mice of angioreactors containing VEGF-A and FGF-enriched 
extracellular matrix. Addition of T0901317 to the extracellular matrix critically reduced 
neoangiogenesis by 86±7% compared to vehicle (p<0.05) (Figure 5C), as assessed by red blood cell 
content in the angioreactors two weeks after implantation. Taken together, these data indicated that 
LXR agonists can inhibit angiogenesis in mouse tissues. 
 
LXR activation inhibits tumor angiogenesis 
Neoangiogenesis is strictly required for tumor growth. To highlight the effect of LXR activation on 
cancer angiogenesis, we used LLC-1 tumor grafts. Contrary to HUVEC, LLC-1 cells did not regulate 
the protein levels of cholesterol transporters ABCA1 and ABCG1 upon treatment with T0901317 
(Figure 6A). Also the levels of LDLR were unchanged by T0901317 in LLC-1 cells. Of note, 
T0901317 did not modify the proliferation (Supplementary Figures VA-B), p27/Kip-1 expression 
(Supplementary Figures VC) and apoptosis (Supplementary Figures VD) of LLC-1 cells in vitro. 
LLC-1 cells were thus injected into the flank of wild-type mice, where they gave rise to palpable 
tumors within 7 days. Starting on day 7 post-injection, mice were treated with T0901317 or vehicle 
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daily (20 mg/kg i.p.) for one week. Administration of T0901317 significantly reduced tumor growth 
by 62±20% on day 7 compared to vehicle (p<0.05) (Figure 6B). Body weight remained similar in 
treated and control animals (data not shown). Administration of T0901317 up-regulated ABCA1 
mRNA within the tumor mass (Supplementary Figure VE). In particular, T0901317 significantly 
increased the protein expression of ABCA1 selectively within tumor endothelial cells (Figure 6C). Of 
note, T0901317 treatment reduced the endothelial density of LLC-1 tumors by 50±3% compared to 
vehicle (p<0.01), as assessed by CD31 immunostaining of tumor sections (Figure 6D). Taken 
together, these findings indicated that pharmacological targeting of LXRs can significantly reduce 
tumor angiogenesis.  
 
DISCUSSION 
We provide evidence that LXR activation can restrain angiogenesis. The anti-angiogenic effects of 
LXR agonists are strictly connected to their impact on endothelial cholesterol homeostasis, as co-
incubation of HUVEC or aortic rings with exogenous cholesterol largely neutralized the actions of 
LXR agonists on endothelial tubulogenesis, sprouting and proliferation. These results are in line with 
previous reports that drugs leading to cholesterol deprivation or to impaired cholesterol trafficking, 
such as β-cyclodextrin, itraconazole or high dose statins, can negatively affect angiogenesis.29, 30, 35 In 
endothelial cells, T0901317 lowered cell cholesterol by regulating the expression of multiple targets. 
In particular, LXR activation increased the protein levels of cholesterol transporters ABCA1 and 
ABCG1, which promote cholesterol output towards apolipoprotein A-containing lipoproteins, as well 
as trans-endothelial HDL traffic.28, 36 T0901317 also increased the mRNA expression of IDOL, which 
targets LDLR to ubiquitin-mediated degradation.37 As the expression of LDLR is negligible in 
HUVEC, the effect of LXRs on endothelial cholesterol homeostasis is therefore essentially mediated 
by ABCA1 and ABCG1, at least in vitro. We previously reported that incubation of endothelial cells 
with natural LXR agonist 22(R)-hydroxycholesterol down-regulates the expression of several genes 
controlling cholesterol biosynthesis, such as HMG-CoA reductase, mevalonate kinase and squalene 
epoxidase.19 Hence, natural oxysterol LXR ligands may further impact on endothelial cholesterol 
homeostasis through synergic effects on cholesterol synthesis and traffic. Nonetheless, we cannot 
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exclude that anti-agiogenic effects of LXRs may also relate to so far unappreciated perturbations of 
the non-sterol branch of the mevalonate pathway. For instance, LXR agonists may modify the 
synthesis of isoprenoids and affect protein prenylation, which is required for proper compartmentation 
and function of key proteins involved in angiogenesis (e.g. small GTPases). 
Cholesterol is essential to maintain a normal structure and function of cellular membranes. 
Furthermore, cholesterol-rich microdomains of the plasma membrane called lipid rafts/caveolae 
function as preferential sites for membrane receptor clustering and signaling.15 LXR activation has 
been previously shown to reduce lipid raft size and to restrain lipid-raft associated signaling in a 
cancer cell line.13 We now provide evidence that in endothelial cells, treatment with LXR agonist 
T0901317 specifically impairs biological signals stemming from lipid raft/caveolar domains that are 
critical for angiogenesis. In particular, LXR activation (i) impaired VEGFR2 phosphorylation and 
downstream signaling to PLCγ, and (ii) blunted the compartmentation of VEGFR2 in lipid 
rafts/caveolae. Both effects appear to be mediated by the LXR-dependent perturbation of cholesterol 
homeostasis. These findings are in line with previous data showing that changes in endothelial 
cholesterol affect VEGFR2 signaling, most likely as a result of complex interactions of the receptor 
and its signaling platform within lipid rafts/caveolae.20, 21 Nonetheless, the molecular circuitry linking 
cholesterol balance to angiogenesis is only beginning to emerge. In our study, LXR activation 
significantly reduced caveolin-rich regions of the plasma membrane. As knock-out of caveolin-1 
inhibits angiogenesis by impairing VEGFR2 compartmentation and by causing a detrimental 
deregulation of endothelial NO synthase (eNOS), LXR activation may restrain angiogenesis by 
altering the physiological conditions of caveolin-1 expression and internalization, and possibly eNOS 
activity.38, 39 Furthermore, as lipid rafts/caveolae are membrane microdomains harboring multiple 
signaling platform, we cannot exclude that the effects of LXR activation may extend to other relevant 
receptors and pathways such as those of FGF or TGFβ. 
We provide evidence that the anti-angiogenic effects of LXR activation can be therapeutically 
meaningful, as T0901317 reduced both the vascularization and tumor growth of LLC-1 grafts. Of 
note, the anti-cancer properties of T0901317 were detectable only in vivo, as this drug did not modify 
the proliferation and apoptosis of LLC-1 cells in vitro. The resistance of LLC-1 cells to LXR 
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activation is in line with previous observations that LXR agonists can impair cell cycle progression 
and favor apoptosis (e.g. by increasing the expression of p27/Kip-1) only in certain cancer cell lines, 
while others are resistant to LXR activation.9, 12, 13, 40. It has been suggested that sensitivity to LXR 
agonists may relate to the cell-specific effects of LXRs on cholesterol homoeostasis.31 Our findings 
support this hypothesis, as in LLC-1 cells T0901317 did not modify the expression of both 
cholesterol-handling proteins (ABCA1, ABCG1 and LDLR) and of cell cycle regulator p27/Kip-1. 
Taken together, the present findings picture a scenario where LXR agonists can limit cancer growth in 
vivo by exerting substantial anti-angiogenic effects. Nonetheless, it can be foreseen that in certain 
cancer types, the angiostatic properties of LXR-activating compounds may synergize with direct anti-
proliferative and pro-apoptotic actions of LXRs on tumor cells. As the systemic administration of 
LXR-activating drugs is presently limited by side effects such as liver steatosis and increased LDL-
cholesterol, these drugs may find earlier applications as locally delivered therapies. 
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FIGURE LEGENDS 
Figure 1. LXR activation reduces endothelial cholesterol. (A-E) Relative mRNA expression of LXR 
target genes ABCA1, ABCG1, IDOL, CETP, SREBP1c in HUVEC treated for 18 hours with 
T0901317 (T090, 1 μM) or vehicle (DMSO). *p<0.05, ***p<0.001, n=4. (F) Protein levels of 
ABCA1, ABCG1, CETP, SREBP1c (p=precursor, m=mature) in HUVEC treated for 18 hours with 
T0901317 (1 μM) or vehicle (DMSO). Representative blot of 3 experiments. (G) Cell cholesterol 
(pg/cell) in HUVEC treated for 24 hours with T0901317 (1, 10 μM) or vehicle (DMSO). **p<0.01, 
***p<0.001 versus DMSO, n=4. 
 
Figure 2. LXR activation impairs endothelial migration and tubulogenesis. (A) VEGF-A-induced 
migration of HUVEC treated for 18 hours with GW3965 (1 or 10 μM), T0901317 (T090, 1 or 10 μM) 
or vehicle (DMSO). **p<0.01, ***p<0.001 versus DMSO, n=4. (B) VEGF-A-induced migration of 
LXRβ-silenced (shRNA-LXRβ_2/3) or control HUVEC (shRNA scramble) treated for 18 hours with 
T0901317 (10 μM) or vehicle (DMSO). **p<0.01 versus DMSO, n=4. (C) Matrigel tubulogenesis of 
HUVEC treated for 18 hours with the indicated compounds: vehicle (DMSO), cholesterol (CHOL, 20 
μM), GW3965 (10 μM) or T0901317 (10 μM). Left: representative images of endothelial tubules. 
Right: quantification of relative tubule length per digital image, expressed as % of control (DMSO). 
*p<0.05 versus DMSO, †p<0.05 versus T090+CHOL, n=4. (D) Matrigel tubulogenesis of LXRβ-
silenced (shRNA-LXRβ_2/3) or control HUVEC (shRNA scramble) treated as in B. Left: 
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representative images of endothelial tubules. Right: quantification of relative tubule length per digital 
image, expressed as % of DMSO-treated shRNA scramble. **p<0.01 versus DMSO, n=4. 
 
Figure 3. LXR activation impairs endothelial proliferation without affecting apoptosis. (A) Cell 
growth of HUVEC treated for 48 hours with vehicle (DMSO), GW3965 (1, 5, 10 μM) or T0901317 
(T090, 1, 5, 10 μM). Cell growth was assessed by MTT. ***p<0.001 versus DMSO, n=6. (B) Protein 
levels of cyclin A, cyclin D1 and p27/Kip-1 in HUVEC treated for 24 hours with DMSO or T0901317 
(10 μM). Representative blots of 3 experiments. (C) Apoptosis of HUVEC treated for 24 hours with 
the indicated compounds: vehicle (DMSO), GW3965 (10 μM), T0901317 (10 μM). starve: EBM-2 
medium, GM: EGM-2 medium. ***p<0.01 versus DMSO, n=6. (D) Cell cycle distribution of 
HUVEC treated for 24 hours with vehicle (DMSO), cholesterol (CHOL, 20 μM), T0901317 (10 μM). 
DNA content was determined by PI staining and assessed by FACS analysis (representative 
experiment, n=3). (E) Proliferation rate of HUVEC treated as in D. DNA incorporation of the 
thymidine fluorescent analogue EdU was detected by flow cytometry. The % of proliferating cells is 
indicated (representative experiment, n=3). 
 
Figure 4. LXR activation impairs VEGFR2 signaling and compartmentation in lipid rafts/caveolae. 
(A) Protein levels of phospho-VEGFR2, total VEGFR2 and phospho-PLCγ in HUVEC treated with 
VEGF-A (30 ng/mL, 5 minutes) after incubation for 18 hours with vehicle (DMSO), T0901317 
(T090, 10 μM), cholesterol (CHOL, 20 μM). Representative blots of 4 experiments. (B) 
Quantification of P-VEGFR2 in HUVEC treated as in A. ***p<0.001 versus DMSO, †p<0.05 versus 
T090+CHOL, n=4. (C) Quantification of P-PLCγ in HUVEC treated as in A. ***p<0.001 versus 
DMSO, ††p<0.01 versus T090+CHOL, n=3. (D) Immunofluorescence staining of HUVEC treated for 
18 hours with vehicle (DMSO), T0901317 (10 μM), cholesterol (20 μM).  Representative images of 
Total Internal Reflection Fluorescence (TIRF): red (caveolin-1), green (VEGRF2), blue (DAPI), 
yellow (merge caveolin-1/VEGFR2). (E) Quantification of cell surface caveolin-1-positive area. 
*p<0.05 versus DMSO, †††p<0.001 versus T090+CHOL, n=20. (F) Quantification of cell surface 
VEGFR2 in caveolin-1-positive areas. **p<0.01 versus DMSO, †††p<0.001 versus T090+CHOL, 
 on May 20, 2012 http://submit-atvb.ahajournals.orgATVB/2012/250621, Original Contribution, Downloaded from 
 
 20
n=20. (G-I) Distribution of VEGFR2, flotillin-2 (Flot-2), caveolin-1 (Cav-1) and binding 
immunoglobulin protein (BiP) in the protein fractions obtained from HUVEC (ultracentrifugation on 
a discontinuous sucrose gradient) treated as in D. The lipid raft compartment is represented in the 
lighter fractions (1-3), while the endoplasmic reticulum peaks in the heavier fractions (7-10). 
Representative blots of 3 experiments. 
 
Figure 5. LXR activation impairs angiogenesis in mouse tissues. (A) Endothelial sprouting from 
mouse aortic rings incubated with the indicated compounds for 5 days: vehicle (DMSO), GW3965 (10 
μM), T0901317 (T090, 10 μM), cholesterol (CHOL, 20 μM). Left: representative images of sprouting. 
*p<0.05 versus DMSO, †p<0.05 versus T090+CHOL, n=4. (B) Endothelial sprouting from wild-type 
(WT) and LXRα-/-/LXRβ-/- (LXR-DOKO) aortic rings incubated with vehicle (DMSO) or T0901317 
(10 μM). **p<0.01 versus DMSO, n=4. (C) Neoangiogenesis in angioreactors implanted 
subcutaneously in wild-type mice for two weeks. Left: representative images of explanted 
angioreactors filled with basement membrane extract containing VEGF-A and FGF-2 plus vehicle 
(DMSO) or T0901317 (10 μM). ***p<0.001, n=14. 
 
Figure 6. LXR activation reduces tumor angiogenesis. (A) Protein levels of ABCA1, ABCG1, LDLR 
in HUVEC and LLC-1 cells treated for 18 hours with vehicle (DMSO) or T0901317 (T090, 1 μM). 
Representative blots of 3 experiments.  (B) Growth curve of LLC-1 tumor grafts in mice treated with 
vehicle (CMC-Tween 20) or T0901317 (20 mg/kg i.p. q.d.) for one week. Tumor volume was 
calculated based on daily caliper measurements. *p<0.05, **p<0.01, n=10 mice per group. (C) 
ABCA1/CD31 immunostaining in tumor vessels. Treatments were performed as in B. Left: 
representative images (red: ABCA1, green: CD31, blue: DAPI), 40x magnification, scale bar 30 μm. 
Right: quantification of ABCA1 fluorescence in CD31+ areas. **p<0.01, n=10 per group. (D) CD31 
immunostaining in tumor sections. Treatments were performed as in B. Left: representative images, 
10x magnification, scale bar 100 μm (green: CD31, blue: DAPI). Right: quantification of CD31 
immunofluorescence (% of tumor area). **p<0.01, n=10 per group. 
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